Suppr超能文献

相似文献

1
Structure of aspartoacylase, the brain enzyme impaired in Canavan disease.
Proc Natl Acad Sci U S A. 2007 Jan 9;104(2):456-61. doi: 10.1073/pnas.0607817104. Epub 2006 Dec 28.
2
Mutational analysis of aspartoacylase: implications for Canavan disease.
Brain Res. 2007 May 7;1148:1-14. doi: 10.1016/j.brainres.2007.02.069. Epub 2007 Mar 3.
3
Docking, molecular dynamics and free energy studies on aspartoacylase mutations involved in Canavan disease.
J Mol Graph Model. 2017 Jun;74:44-53. doi: 10.1016/j.jmgm.2017.03.011. Epub 2017 Mar 19.
4
Identification of the zinc binding ligands and the catalytic residue in human aspartoacylase, an enzyme involved in Canavan disease.
FEBS Lett. 2006 Oct 30;580(25):5899-904. doi: 10.1016/j.febslet.2006.09.056. Epub 2006 Oct 2.
5
Purification and preliminary characterization of brain aspartoacylase.
Arch Biochem Biophys. 2003 May 1;413(1):1-8. doi: 10.1016/s0003-9861(03)00055-9.
6
Aspartoacylase catalytic deficiency as the cause of Canavan disease: a structural perspective.
Biochemistry. 2014 Aug 5;53(30):4970-8. doi: 10.1021/bi500719k. Epub 2014 Jul 16.
7
Examination of the mechanism of human brain aspartoacylase through the binding of an intermediate analogue.
Biochemistry. 2008 Mar 18;47(11):3484-92. doi: 10.1021/bi702400x. Epub 2008 Feb 23.
8
N-acetylaspartate supports the energetic demands of developmental myelination via oligodendroglial aspartoacylase.
Neurobiol Dis. 2016 Dec;96:323-334. doi: 10.1016/j.nbd.2016.10.001. Epub 2016 Oct 4.
10
Murine aspartoacylase: cloning, expression and comparison with the human enzyme.
Brain Res Mol Brain Res. 2000 May 5;77(2):285-9. doi: 10.1016/s0169-328x(00)00068-1.

引用本文的文献

2
Cellular and molecular mechanisms of aspartoacylase and its role in Canavan disease.
Cell Biosci. 2024 Apr 6;14(1):45. doi: 10.1186/s13578-024-01224-6.
4
Temporal Alterations in White Matter in An Knock-In Mouse Model of Alzheimer's Disease.
eNeuro. 2024 Feb 26;11(2). doi: 10.1523/ENEURO.0496-23.2024. Print 2024 Feb.
5
Aspartoacylase suppresses prostate cancer progression by blocking LYN activation.
Mil Med Res. 2023 Jun 5;10(1):25. doi: 10.1186/s40779-023-00460-0.
7
Myelination Deficits in the Auditory Brainstem of a Mouse Model of Fragile X Syndrome.
Front Neurosci. 2021 Nov 11;15:772943. doi: 10.3389/fnins.2021.772943. eCollection 2021.
8
Mapping the degradation pathway of a disease-linked aspartoacylase variant.
PLoS Genet. 2021 Apr 29;17(4):e1009539. doi: 10.1371/journal.pgen.1009539. eCollection 2021 Apr.
10
Comparative computational assessment of the pathogenicity of mutations in the Aspartoacylase enzyme.
Metab Brain Dis. 2017 Dec;32(6):2105-2118. doi: 10.1007/s11011-017-0090-5. Epub 2017 Sep 6.

本文引用的文献

2
Processing of X-ray diffraction data collected in oscillation mode.
Methods Enzymol. 1997;276:307-26. doi: 10.1016/S0076-6879(97)76066-X.
3
Aspartoacylase is a regulated nuclear-cytoplasmic enzyme.
FASEB J. 2006 Oct;20(12):2139-41. doi: 10.1096/fj.05-5358fje. Epub 2006 Aug 25.
4
N-acetylaspartate as a reservoir for glutamate.
Med Hypotheses. 2006;67(3):506-12. doi: 10.1016/j.mehy.2006.02.047. Epub 2006 May 26.
5
Characterization of human aspartoacylase: the brain enzyme responsible for Canavan disease.
Biochemistry. 2006 May 9;45(18):5878-84. doi: 10.1021/bi052608w.
6
Canavan disease and the role of N-acetylaspartate in myelin synthesis.
Mol Cell Endocrinol. 2006 Jun 27;252(1-2):216-23. doi: 10.1016/j.mce.2006.03.016. Epub 2006 May 2.
9
Magnetic resonance spectroscopy.
J Neuroophthalmol. 2005 Sep;25(3):217-26. doi: 10.1097/01.wno.0000177307.21081.81.
10
Possible genotype-phenotype correlations in children with mild clinical course of Canavan disease.
Neuropediatrics. 2005 Aug;36(4):252-5. doi: 10.1055/s-2005-865865.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验